메뉴 건너뛰기




Volumn 11, Issue 4, 2017, Pages 400-411

Long-term efficacy of vedolizumab for ulcerative colitis

(18)  Loftus, Edward V a   Colombel, Jean Frédéric b   Feagan, Brian G c   Vermeire, Severine d   Sandborn, William J e   Sands, Bruce E b   Danese, Silvio f   D'Haens, Geert R g   Kaser, Arthur h   Panaccione, Remo i   Rubin, David T j   Shafran, Ira k   McAuliffe, Megan l   Kaviya, Arpeat m   Sankoh, Serap l   Mody, Reema n   Abhyankar, Brihad m   Smythm, Michael m  


Author keywords

Long term efficacy; Ulcerative colitis; Vedolizumab

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID DERIVATIVE; EFALIZUMAB; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; PLACEBO; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; VEDOLIZUMAB; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

EID: 85019608509     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjw177     Document Type: Article
Times cited : (185)

References (30)
  • 4
    • 84867359637 scopus 로고    scopus 로고
    • Vedolizumab for the treatment of ulcerative colitis and Crohn's disease
    • McLean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. Immunotherapy 2012;4:883-98.
    • (2012) Immunotherapy , vol.4 , pp. 883-898
    • McLean, L.P.1    Shea-Donohue, T.2    Cross, R.K.3
  • 5
    • 4344602852 scopus 로고    scopus 로고
    • Guidelines for the management of inflammatory bowel disease in adults
    • Carter MJ, Lobo AJ, Travis SP, IBD Section Bristish Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53:v1-v16.
    • (2004) Gut , vol.53 , pp. V1-V16
    • Carter, M.J.1    Lobo, A.J.2    Travis, S.P.3
  • 6
    • 84925664186 scopus 로고    scopus 로고
    • Tumor necrosis factoralpha antagonists twenty years later: What do Cochrane reviews tell us?
    • Akobeng AA, Sandborn WJ, Bickston SJ, et al. Tumor necrosis factoralpha antagonists twenty years later: What do Cochrane reviews tell us? Inflamm Bowel Dis 2014;20:2132-41.
    • (2014) Inflamm Bowel Dis , vol.20 , pp. 2132-2141
    • Akobeng, A.A.1    Sandborn, W.J.2    Bickston, S.J.3
  • 7
    • 84866122837 scopus 로고    scopus 로고
    • Serious infection and mortality in patients with Crohn's disease: More than 5 years of follow-up in the TREAT registry
    • Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: More than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012;107:1409-22.
    • (2012) Am J Gastroenterol , vol.107 , pp. 1409-1422
    • Lichtenstein, G.R.1    Feagan, B.G.2    Cohen, R.D.3
  • 8
    • 84925485488 scopus 로고    scopus 로고
    • Vedolizumab: A review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease
    • Garnock-Jones KP. Vedolizumab: A review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease. BioDrugs 2015;29:57-67.
    • (2015) BioDrugs , vol.29 , pp. 57-67
    • Garnock-Jones, K.P.1
  • 9
    • 0030802049 scopus 로고    scopus 로고
    • Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue
    • Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997;151:97-110.
    • (1997) Am J Pathol , vol.151 , pp. 97-110
    • Briskin, M.1    Winsor-Hines, D.2    Shyjan, A.3
  • 10
    • 84867576762 scopus 로고    scopus 로고
    • Exclusive antagonism of the a4ß7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates
    • Fedyk ER, Wyant T, Yang LL, et al. Exclusive antagonism of the a4ß7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis 2012;18:2107-19.
    • (2012) Inflamm Bowel Dis , vol.18 , pp. 2107-2119
    • Fedyk, E.R.1    Wyant, T.2    Yang, L.L.3
  • 11
    • 70349086185 scopus 로고    scopus 로고
    • The binding specificity and selective antagonism of vedolizumab, an anti-a4ß7 integrin therapeutic antibody in development for inflammatory bowel diseases
    • Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-a4ß7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009;330:864-75.
    • (2009) J Pharmacol Exp Ther , vol.330 , pp. 864-875
    • Soler, D.1    Chapman, T.2    Yang, L.L.3
  • 12
    • 0029826678 scopus 로고    scopus 로고
    • Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin a4ß7
    • Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin a4ß7. Gastroenterology 1996;111:1373-80.
    • (1996) Gastroenterology , vol.111 , pp. 1373-1380
    • Hesterberg, P.E.1    Winsor-Hines, D.2    Briskin, M.J.3
  • 13
    • 84929773619 scopus 로고    scopus 로고
    • Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab
    • Wyant T, Estevam J, Yang L, Rosario M. Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab. Cytometry B Clin Cytom 2016;90:168-76.
    • (2016) Cytometry B Clin Cytom , vol.90 , pp. 168-176
    • Wyant, T.1    Estevam, J.2    Yang, L.3    Rosario, M.4
  • 14
    • 84882769357 scopus 로고    scopus 로고
    • Vedolizumab as induction and maintenance therapy for ulcerative colitis
    • Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
    • (2013) N Engl J Med , vol.369 , pp. 699-710
    • Feagan, B.G.1    Rutgeerts, P.2    Sands, B.E.3
  • 15
    • 0003871544 scopus 로고    scopus 로고
    • World Medical Association [WMA] Declaration of Helsinki -ethical principles for medical research involving human subjects
    • Accessed December 22
    • World Medical Association. World Medical Association [WMA] Declaration of Helsinki -ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/ Accessed December 22, 2014.
    • (2014)
  • 16
    • 84884538154 scopus 로고    scopus 로고
    • Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease
    • Parikh A, Fox I, Leach T, et al. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:1691-9.
    • (2013) Inflamm Bowel Dis , vol.19 , pp. 1691-1699
    • Parikh, A.1    Fox, I.2    Leach, T.3
  • 17
    • 84986574933 scopus 로고    scopus 로고
    • Risk assessment and minimization for progressive multifocal leukoencephalopathy (PML) (RAMP): A program to assess the potential early signs and symptoms of PML during clinical development of vedolizumab
    • Clifford D, McAuliffe M, Stephens K, et al. Risk assessment and minimization for progressive multifocal leukoencephalopathy (PML) (RAMP): A program to assess the potential early signs and symptoms of PML during clinical development of vedolizumab. Am J Gastroenterol 2013;108:S502.
    • (2013) Am J Gastroenterol , vol.108 , pp. S502
    • Clifford, D.1    McAuliffe, M.2    Stephens, K.3
  • 18
    • 58149388237 scopus 로고    scopus 로고
    • Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial
    • Loftus EV, Feagan BG, Colombel JF, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008;103:3132-41.
    • (2008) Am J Gastroenterol , vol.103 , pp. 3132-3141
    • Loftus, E.V.1    Feagan, B.G.2    Colombel, J.F.3
  • 19
    • 63849147312 scopus 로고    scopus 로고
    • Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease
    • Coteur G, Feagan B, Keininger DL, Kosinski M. Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease. Aliment Pharmacol Ther 2009;29:1032-41.
    • (2009) Aliment Pharmacol Ther , vol.29 , pp. 1032-1041
    • Coteur, G.1    Feagan, B.2    Keininger, D.L.3    Kosinski, M.4
  • 20
    • 84931563838 scopus 로고    scopus 로고
    • Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
    • Rosario M, Dirks NL, Gastonguay MR, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther 2015;42:188-202.
    • (2015) Aliment Pharmacol Ther , vol.42 , pp. 188-202
    • Rosario, M.1    Dirks, N.L.2    Gastonguay, M.R.3
  • 21
    • 85029021557 scopus 로고    scopus 로고
    • Corticosteroid dose reduction in ulcerative colitis patients treated with vedolizumab during the GEMINI 1 trial
    • Loftus EV, Siegel C, Panaccione R, et al. Corticosteroid dose reduction in ulcerative colitis patients treated with vedolizumab during the GEMINI 1 trial. Am J Gastroenterol 2015;110:S790.
    • (2015) Am J Gastroenterol , vol.110 , pp. S790
    • Loftus, E.V.1    Siegel, C.2    Panaccione, R.3
  • 22
    • 2442560536 scopus 로고    scopus 로고
    • The Inflammatory Bowel Disease Questionnaire: A review of its national validation studies
    • Pallis AG, Mouzas IA, Vlachonikolis IG. The Inflammatory Bowel Disease Questionnaire: A review of its national validation studies. Inflamm Bowel Dis 2004;10:261-9.
    • (2004) Inflamm Bowel Dis , vol.10 , pp. 261-269
    • Pallis, A.G.1    Mouzas, I.A.2    Vlachonikolis, I.G.3
  • 23
    • 0036863322 scopus 로고    scopus 로고
    • Validation of the EuroQol questionnaire in patients with inflammatory bowel disease
    • Konig HH, Ulshofer A, Gregor M, et al. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002;14:1205-15.
    • (2002) Eur J Gastroenterol Hepatol , vol.14 , pp. 1205-1215
    • Konig, H.H.1    Ulshofer, A.2    Gregor, M.3
  • 24
    • 1942473594 scopus 로고    scopus 로고
    • A comparison of the discriminatory power of the Inflammatory Bowel Disease Questionnaire and the SF-36 in people with ulcerative colitis
    • McColl E, Han SW, Barton JR, Welfare MR. A comparison of the discriminatory power of the Inflammatory Bowel Disease Questionnaire and the SF-36 in people with ulcerative colitis. Qual Life Res 2004;13:805-11.
    • (2004) Qual Life Res , vol.13 , pp. 805-811
    • McColl, E.1    Han, S.W.2    Barton, J.R.3    Welfare, M.R.4
  • 25
    • 84886946831 scopus 로고    scopus 로고
    • Optimizing anti-TNF treatments in inflammatory bowel disease
    • Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 2014;13:24-30.
    • (2014) Autoimmun Rev , vol.13 , pp. 24-30
    • Ben-Horin, S.1    Kopylov, U.2    Chowers, Y.3
  • 26
    • 85029043209 scopus 로고    scopus 로고
    • Takeda. Entyvio (vedolizumab) [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.
    • Takeda. Entyvio (vedolizumab) [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc., 2014.
    • (2014)
  • 27
    • 85028977058 scopus 로고    scopus 로고
    • Effects of increased vedolizumab dosing frequency on disease activity in ulcerative colitis and Crohn's disease
    • Sands BE, Dubinsky M, Vermeire S, et al. Effects of increased vedolizumab dosing frequency on disease activity in ulcerative colitis and Crohn's disease. Am J Gastroenterol 2014;109:S478-S9.
    • (2014) Am J Gastroenterol , vol.109 , pp. S478-S479
    • Sands, B.E.1    Dubinsky, M.2    Vermeire, S.3
  • 28
    • 84866457923 scopus 로고    scopus 로고
    • Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease
    • quiz e85-6
    • Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012;10:1079-87; quiz e85-6.
    • (2012) Clin Gastroenterol Hepatol , vol.10 , pp. 1079-1087
    • Ordas, I.1    Feagan, B.G.2    Sandborn, W.J.3
  • 29
    • 79953788656 scopus 로고    scopus 로고
    • Assessing response and loss of response to biological therapies in IBD
    • Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106:685-98.
    • (2011) Am J Gastroenterol , vol.106 , pp. 685-698
    • Yanai, H.1    Hanauer, S.B.2
  • 30
    • 84960145681 scopus 로고    scopus 로고
    • The safety of vedolizumab for ulcerative colitis and Crohn's disease
    • Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2016. doi: 10.1136/ gutjnl-2015-311079. [Epub ahead of print].
    • Gut , vol.2016
    • Colombel, J.F.1    Sands, B.E.2    Rutgeerts, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.